The Google DeepMind research team is developing a new AI model called ' AlphaGenome,' which can analyze long DNA sequences up to one million characters long at a time and predict 11 major genomic ...

This is an important study that identifies the developmental time window during which re-expression of TCF4 mutated in Pitt-Hopkins syndrome, can rescue phenotypic features of brain function in a TCF4 ...

A research team at the IPK Leibniz Institute has developed a method that enables the detailed observation of female ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Researchers from New England Biolabs and Yale University have created a system for engineering the first fully synthetic ...

Retrotransposons are pivotal in human genome evolution, driving structural variation and regulatory innovation while influencing health and disease.

Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 3.5% Wednesday after the precision medicine technology company announced the launch of its new HRD-RNA algorithm for cancer detection.

Accent Therapeutics launched a Phase I/II clinical trial last year to begin testing a small molecule inhibitor of KIF18A in ovarian cancers.

A study published in Nature has established the first direct link between common genetic variants in mothers and the risk of ...

Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 - ...